Lonza announced Swissmedic has granted GMP approval for its new aseptic drug‑product filling line in Stein, Switzerland, enabling contained manufacturing of highly potent biologics including ADCs. The facility uses advanced isolator and containment systems aligned with Annex 1 sterile manufacturing requirements and links to Lonza’s Basel drug substance capabilities to offer integrated drug substance–drug product supply. The line expands capacity for liquid and lyophilized vial filling and is positioned to support both clinical and commercial supply across monoclonal antibodies, bispecifics and ADCs. Lonza highlighted the capability as part of its strategy to capture end‑to‑end biologics workstreams for customers seeking single‑partner solutions. Operational readiness for highly potent biologics addresses a tight market for specialized fill/finish slots and could shorten commercialization timelines for sponsors developing ADCs and other constrained modalities.